New Horizons Diagnostics (United States)

Life's dependence on adenosine triphosphate (ATP) makes its synthesis one of the most important biochemical processes in nature. During ATP synthesis, the (Mg 2+)-adenosine diphosphate (ADP) complex is formed. It has been posited that magnetic field effects (MFEs) may arise through intermediate access of a radical pair state. Prior studies have invoked radical pair mechanisms to explain MFEs and magnetic isotope effects (MIEs) in enzymes involved in ATP synthesis. However, the microscopic conditions required for such effects to occur-and to be reproducibly measured-have not been clearly established. In this work, we investigate the microscopic conditions required for MFEs in the ADP-Mg dimer and identify the criteria for magnetic field sensitivity. Thermal suppression of singlet pathways was observed in the low-moderate magnetic field regime. Corresponding triplet populations exhibited a robust bimodality, with a dominant orientation-independent maximum near 2.2 mT alongside a secondary orientation-dependent maximum at 50 mT. Modelling of MIEs from Mg revealed minimal differences in the spin statistics, suggesting that MIEs are a secondary factor rather than a governing determinant. Embedding these field-dependent spin populations within a time evolution framework demonstrated that MFEs shift the balance between productive and unproductive radical pair recombination, yielding an up to 5-fold increase in effective ATP yields. These results establish a concrete physical basis for magnetic sensitivity of radical pair dynamics in ATP synthesis, and delineate field regimes in which spin-state populations can, in principle, couple to bioenergetic chemistry, while also elucidating the conditions key to observing MFEs in ATP synthesis.

We read with interest the article by Bobelyak and colleagues and the accompanying Editorial.However, we have serious concerns about the article's methodology and conclusions.The authors reported REMS-BMD measurements at the proximal femur in patients before and after hip arthroplasty and, based on minimal changes in BMD and variations observed with different anthropometric inputs, concluded that REMS-BMD is essentially derived from age, sex, and BMI rather than from ultrasound spectral data.This conclusion is not supported by the evidence provided, which highlight instead technical errors and misinterpretations of REMS operating principles, as detailed below.

Introduction/Purpose Subdural hematomas (SDHs) are among the most common neurosurgical conditions, particularly affecting the elderly. Standard treatment paradigms include surgical evacuation and, more recently, middle meningeal artery embolization (MMAe) to prevent recurrence. These interventions are typically performed as separate procedures by different teams, often under general anesthesia. This fragmented approach introduces inefficiencies, procedural risks, and access barriers—especially for frail or medically complex patients.To address these limitations, we developed the first endovascular system enabling single‐session , fully transvascular treatment of non‐acute SDH. The procedure integrates MMA embolization and catheter‐based subdural evacuation through the same arterial access, obviating the need for craniotomy. A proprietary system of devices allow controlled perforation of the arterial wall and dura, enabling catheter navigation into the subdural space for drainage. Materials and Methods In a prospective, single‐arm, first‐in‐human study (EMBODRAIN), we enrolled 16 consecutive patients with symptomatic non‐acute SDH. Two patients were excluded due to anatomical reasons (diminutive MMA in one case, and MMA emerging from ophthalmic artery in one case). Patients were followed clinically and radiographically for 30 days. Results All fourteen treated patients (mean age 73.6 years; 80% male) underwent successful MMA embolization and transvascular subdural drainage without intraoperative complications or need for surgical backup. SDH volume was reduced by >65% in average. Midline shift improved from 9.7 ± 3.8 mm to 4.2 ± 2.1 mm. Functional status also improved rapidly: Modified Rankin Scale (mRS) scores decreased from a mean of 2.7 to 1.3, and Markwalder Grading Scale scores from 1.9 to 0.7 within 72 hours. There were no hemorrhagic complications, neurologic deteriorations, or radiographic reaccumulations. No patients required ICU admission or anticoagulation reversal. Conclusions This first‐in‐human experience establishes the safety, technical feasibility, and early clinical effectiveness of fully endovascular treatment of non‐acute SDH. The approach provides a streamlined, minimally invasive solution that integrates embolization and hematoma evacuation into a single transvascular session. Beyond SDH, this technology lays the foundation for transvascular neurosurgery —a new paradigm that utilizes endovascular access to treat traditionally non‐vascular intracranial pathologies. Its potential to transform intracranial therapeutics, improve access, and reduce treatment morbidity is significant and warrants further clinical investigation. image FundingSupportResearch : National Institutes of Health (NIH)

In recent years, across many segments of the biomedical research enterprise and the health care delivery sectors, the impact of biomarkers has been transforming in many ways: from business and economics to policy and planning of disease management. Clinical applications of biomarkers in medical practice are also coming more into focus through diagnostics and molecularly targeted therapies. This article discusses the medical research history that led to the shaping of new directions that is captured simply by the term biomarker, a biological indicator of health or disease. Keywords: biomedical research; health care delivery; biomarkers; biological indicator

Purpose – In little more than a decade, experience thinking has influenced the development of new business models in a wide variety of enterprises. Design/methodology/approach – The authors describe best practices for five approaches Five approaches are noteworthy: Experiential marketing (EM or XM). Digital experiences using the Internet and other electronic platforms to create new technology interfaces focused on the user experience (UX). The application of experience-staging to enhance interactions with customers. Experiences as a distinct economic offering. Designing transformational business models that allows the company to charge for the demonstrated outcomes customers achieve. Findings – Companies can innovate by recognizing trends in customer needs and aspirations that provide opportunities to develop business models that offer high value experiences or even customer transformations. Originality/value – To truly pursue experiences as a distinct form of economic output, companies must design a business model that involves charging for the time customers spend engaging with the business, such as an admission or membership fee of some sort.